Stephanie Link, whose "Halftime Report" model portfolio is up 7 percent this year, believes shares of Lear are poised to rise from here.» Read More
The dramatic 10-month drop in the price of oil could be due to ultra-loose monetary policy by the U.S. Federal Reserve, according to a senior analyst.
Oppenheimer's Ari Wald says the chart of crude reminds him strongly of 2009. And that's good news for the oil bulls.
It's still early in this earnings reporting season, but a worrisome trend is unfolding and if it continues, it could undermine the bull market.
The Federal Reserve has removed one crutch for stocks and left another in place, Peter Boockvar tells CNBC. Earnings are now the variable to watch.
"It has been unremittingly horrible for someone like me who has been long value, short over-hyped stocks," one short-seller said.
Morgan Stanley analyst says Mobileye is a pure play to invest in self-driving cars.
The "Fast Money" traders give their final trades of the day.
IRA owners will want to know about these new IRA rules before planning their estate or transferring money between IRAs.
Jim Cramer shares a big discovery in his research—one of the best times to buy a stock is when analyst estimates are cut. Here's how to spot it.
Jim Cramer shares the numbers to watch in picking a winning stock. Just because you are diversified, doesn't mean you're not making this big mistake.
“Mad Money” host Jim Cramer shares how you can tell a stock has reached a buyable bottom.
Jim Cramer shares with investors how to recognize signals of when to fold. Could it be time to walk away?
Aren't secondary offerings negative for shareholders? Jim Cramer says that’s not always the case.
Fast-growing Stone Ridge Asset Management has poached execs from Credit Suisse, BNP Paribas and Morgan Stanley in recent weeks.
Regulatory changes for trading Chinese stocks spooked European and U.S. markets on Friday.
The European Union's antitrust suit against Google is not the first. The euro zone has a history of going after big American tech firms.
The stock market slides big to end the week. Is there more downside ahead? And is the consumer in trouble? With CNBC's Melissa Lee and the Options Action traders.
Is there anything to "like" about Facebook heading into earnings? A look ahead of earnings, with CNBC's Melissa Lee and the Options Action traders.
Biotech investors are going to be busy with new data on Alzheimer's drugs, cancer and genetic disorders on the way. Here's what analysts are watching.
Get ready for more market gyrations, but in the long run stocks will rise, strategist Savita Subramanian says as share prices plunge.